AdAlta Limited

Equities

1AD

AU0000001AD2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:11:12 24/05/2024 BST			5-day change	1st Jan Change
0.026 ^AUD	0.00%		+8.33%	+8.33%

05-13	AdAlta Signs Master Services Agreement with Cell Therapies; Shares Up 4%	MT
04-29	AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	MT

AdAlta links AD-214 results with efficacy thanks to new data

July 07, 2023 at 07:11 pm

(via NewsDirect)

AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactive’s Elisha Newell that new data on lead drug candidate AD-214 favourably links preclinical animal studies and Phase I human trial results, providing important dose frequency insights as it moves through the clinic. The findings de-risk the I-body candidate’s future move into Phase 2 clinical trials and stand to boost confidence as AdAlta progresses partnership discussions. Oldham says the new data is “critically important” and a credit to AdAlta’s in-house scientific team.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about AdAlta Limited

AdAlta Signs Master Services Agreement with Cell Therapies; Shares Up 4%	05-13	MT
AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	04-29	MT
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	04-08	MT
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	12-19	MT
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	11-22	MT
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	11-07	MT
AdAlta to Seeks AU$1.2 Million from Share Placement	11-03	MT
AdAlta Receives AU$2.4 Million R&D Tax Rebate	18/10/23	MT
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	20/09/23	MT
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	04/08/23	MT
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility	13/07/23	MT
AdAlta Secures Ethics Approval for Phase One Clinical Trial	29/06/23	MT
AdAlta Raises AU$1.3 Million Via Rights Offer	25/05/23	MT
Adalta Limited Announces Retirement of Elizabeth Mccall as Non-Executive Director	23/03/23	CI
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
Journal of Biological Chemistry Highlights Potential of Adalta's i-Body Platform for Treating Osteoporosis	26/01/23	MT
Australian Researchers Demonstrate AdAlta's i-Body Platform's Treatment Potential for Osteoporosis	25/01/23	MT
Adalta Welcomes Two Investors Associated with Yuuwa Capital	24/01/23	MT
AdAlta Secures Second Patent for I-body Candidate	10/01/23	MT
AdAlta Limited Provides an Update on Its Lead Program, AD-214	01/11/22	CI
Australian Shares in the Red as US Fed Likely to Continue Rate Hikes	13/10/22	MT
Adalta, GPCR Therapeutics to Evaluate New Cancer Treatment Approach	13/10/22	MT
AdAlta Limited & GPCR Therapeutics, Inc. to Evaluate CXCR4 I-Bodies in Cancer	12/10/22	CI

Chart AdAlta Limited

Duration

Period

More charts

Company Profile

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patientâs immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patientâs immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADALTA LIMITED	+8.33%	9.19M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs